Literature DB >> 11694739

Pregnancy outcome and prognosis in fetuses with increased first-trimester nuchal translucency.

R Mangione1, F Guyon, L Taine, Z Q Wen, D Roux, A Vergnaud, B Maugey-Laulom, J Horovitz, R Saura.   

Abstract

OBJECTIVE: One of the concerns of prenatal diagnosis is to find sensitive markers to screen for chromosome abnormalities, such as serum assays or nuchal translucency (NT). This study reports our experience with NT measurement during the first trimester of pregnancy. MATERIALS: The study was performed prospectively on 252 fetuses with either NT > or =3 mm or cystic hygroma.
RESULTS: We observed 50 abnormal karyotypes, i.e. 19.8%. The incidence of chromosome abnormalities increased with increasing maternal age and increasing NT thickness. For the 202 fetuses with normal karyotypes, outcome was unfavourable in 32 cases: 23 elective terminations of pregnancy, 8 spontaneous abortions and 1 neonatal death. Outcome was favourable in 141 cases. Twenty-nine pregnancies were lost to follow-up.
CONCLUSION: Measurement of NT at 12 weeks' gestation seems to be a good marker for chromosome abnormalities. When the karyotype is normal, the pregnancy outcome remains correlated with the degree of NT thickness. The finding of NT >3 mm between 10 and 14 weeks' gestation dictates rigorous ultrasound monitoring and caution when predicting pregnancy outcome. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2001        PMID: 11694739     DOI: 10.1159/000053941

Source DB:  PubMed          Journal:  Fetal Diagn Ther        ISSN: 1015-3837            Impact factor:   2.587


  9 in total

1.  Significance of septa in first trimester increased nuchal translucency thickness.

Authors:  Aytul Corbacioglu Esmer; Ibrahim Kalelioglu; Betul Keyif; Mehmet Ozsurmeli; Atıl Yüksel; Recep Has
Journal:  J Med Ultrason (2001)       Date:  2013-06-19       Impact factor: 1.314

Review 2.  First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

Review 3.  First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

Review 4.  Second trimester serum tests for Down's Syndrome screening.

Authors:  S Kate Alldred; Jonathan J Deeks; Boliang Guo; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13

Review 5.  Adverse pregnancy outcomes after abnormal first-trimester screening for aneuploidy.

Authors:  Laura Goetzl
Journal:  Clin Lab Med       Date:  2010-09       Impact factor: 1.935

6.  Increased nuchal translucency before 11 weeks of gestation: Reason for referral?

Authors:  Malou A Lugthart; Bo B Bet; Fleur Elsman; Karline van de Kamp; Bernadette S de Bakker; Ingeborg H Linskens; Merel C van Maarle; Elisabeth van Leeuwen; Eva Pajkrt
Journal:  Prenat Diagn       Date:  2021-10-08       Impact factor: 3.242

7.  Prenatal diagnosis of 4953 pregnant women with indications for genetic amniocentesis in Northeast China.

Authors:  Rulin Dai; Yang Yu; Qi Xi; Xiaonan Hu; Haibo Zhu; Ruizhi Liu; Ruixue Wang
Journal:  Mol Cytogenet       Date:  2019-11-06       Impact factor: 2.009

Review 8.  First trimester serum tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2015-11-30

Review 9.  Urine tests for Down's syndrome screening.

Authors:  S Kate Alldred; Boliang Guo; Yemisi Takwoingi; Mary Pennant; Susanna Wisniewski; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2015-12-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.